ArticleScientific reports2021
A vascularized tumoroid model for human glioblastoma angiogenesis.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- 3D triply periodic minimal surface gyroid hydrogel scaffolds for soft tissue engineering.Nature communications · 2026Article
- Organoids to Model Tumor Microenvironment in Progression of Pathogenesis and Treatment Resistance in Glioblastoma Multiforme.Brain sciences · 2026Review
- Impact of postoperative blood pressure management on postoperative hemorrhage after resection of intraparenchymal brain tumors.Acta neurochirurgica · 2026Article
- Review
- A mechanobiology-driven cell-derived ECM bioink for engineering 3D glioblastoma tumor microenvironment models.Theranostics · 2026Article
- Human preclinical multiple myeloma in vitro models for disease modeling and therapy screening.Journal of biological engineering · 2025Review
- Advancing glioblastoma therapy with surface-modified nanoparticles.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Review
- Ultrasmall nanoparticles for co-delivery of antisense oligonucleotides targeting miR-21 and miR-210 to treat glioblastoma.Journal of nanobiotechnology · 2025Article
- Recent advances in 3D printing applications for CNS tumours.European journal of medical research · 2025Review
- Personalising glioblastoma medicine: explant organoid applications, challenges and future perspectives.Acta neuropathologica communications · 2025Review
- Practical immunomodulatory landscape of glioblastoma multiforme (GBM) therapy.Journal of the Egyptian National Cancer Institute · 2024Review
- Tumoroids, a valid preclinical screening platform for monitoring cancer angiogenesis.Stem cell research & therapy · 2024Review
- The role of postoperative blood pressure management in early postoperative hemorrhage in awake craniotomy glioma patients.Neurosurgical review · 2024Article
- Recurrent Glioblastoma-Molecular Underpinnings and Evolving Treatment Paradigms.International journal of molecular sciences · 2024Review
- A 3D Bioprinted Human Neurovascular Unit Model of Glioblastoma Tumor Growth.Advanced healthcare materials · 2024Article
- Rebuilding the microenvironment of primary tumors in humans: a focus on stroma.Experimental & molecular medicine · 2024Review
- Vascularization ability of glioma stem cells in different three-dimensional microenvironments.Regenerative biomaterials · 2024Article
- The Glioblastoma CircularRNAome.International journal of molecular sciences · 2023Review
- Engineered Vasculature for Cancer Research and Regenerative Medicine.Micromachines · 2023Review
- PVA-Microbubbles as a Radioembolization Platform: Formulation and the In Vitro Proof of Concept.Pharmaceutics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma (GBM) angiogenesis is critical for tumor growth and recurrence, making it a compelling therapeutic target. Here, a disease-relevant, vascularized tumoroid in vitro model with stem-like features and stromal surrounds is reported. The model is used to recapitulate how individual components of the GBM's complex brain microenvironment such as hypoxia, vasculature-related stromal cells and growth factors support GBM angiogenesis. It is scalable, tractable, cost-effective and can be used with biologically-derived or biomimetic matrices. Patient-derived primary GBM cells are found to closely participate in blood vessel formation in contrast to a GBM cell line containing differentiated cells. Exogenous growth factors amplify this effect under normoxia but not at hypoxia suggesting that a significant amount of growth factors is already being produced under hypoxic conditions. Under hypoxia, primary GBM cells strongly co-localize with umbilical vein endothelial cells to form sprouting vascular networks, which has been reported to occur in vivo. These findings demonstrate that our 3D tumoroid in vitro model exhibits biomimetic attributes that may permit its use as a preclinical model in studying microenvironment cues of tumor angiogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.